<unk>  is a two-drug combination of<unk> , a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and<unk> , a HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) that is FDA approved for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of<unk> .   Common adverse reactions include diarrhea and headache.
Dolutegravir / rilpivirine
Sofosbuvir / velpatasvir
Elbasvir / grazoprevir
Ledipasvir / sofosbuvir
Bictegravir / emtricitabine / tenofovir alafenamide
Glecaprevir / pibrentasvir
Lopinavir ritonavir
Atazanavir and cobicistat